7.1. neoadjuvant therapy. 7.1.1. introduction standard treatment patients urothelial mibc mibc subtypes rc. however, rc provides 5-year survival 50% patients [248-250]. improve survival patients cn0m0 disease, cisplatin-based nac used since 1980s [248-252]. 7.1.2. role cisplatin-based chemotherapy theoretical advantages disadvantages administering chemotherapy planned definitive surgery patients resectable muscle-invasive cn0m0 uc bladder: chemotherapy delivered earliest time-point, burden micrometastatic disease expected low.potential reflection vivo chemosensitivity.tolerability chemotherapy patient compliance expected better pre-cystectomy.patients may respond nac favourable pathological response determined mainly achieving ypt0, ≤ ypt1, ypn0 negative surgical margins. analysis identify optimal definition pathological response reported significantly higher risk recurrence patients yptan0 ypt1n0 disease (with without tis) rc thus proposed optimal pathological response nac defined attainment ypt0n0/yptisn0 rc .delayed cystectomy might compromise outcome patients sensitive chemotherapy [254-256]. comparative survival analysis patients treated nac rc vs. rc alone based data u.s. national cancer database showed organ-confined disease (≤ pt2) nac associated decreased risk death (hr: 0.85, 95% ci: 0.79–0.91) compared rc alone, whereas > pt2 associated increased risk death (hr: 1.46, 95% ci: 1.34–1.60) . however, prospective trials indicating delayed surgery due nac negative impact survival. phase iii vesper trial, comparing gemcitabine/cisplatin (gc) vs. high-dose-intensity methotrexate, vinblastine, doxorubicine cisplatin (hd-mvac) peri-operative setting, approximately 90% patients proceeded surgery (with median delay 48 days gc 51 days dd-mvac) .neoadjuvant chemotherapy seem affect outcome surgical morbidity. recently reported large multicenter retrospective analysis, nac lead increased risk post-operative complications rc . combined nordic trials (n = 620), nac major adverse effect percentage performable cystectomies. cystectomy frequency 86% experimental arm 87% control arm 71% patients receiving three chemotherapy cycles .clinical staging using bimanual palpation, ct mri may result over- understaging staging accuracy 70% . overtreatment possible negative consequence.gender may impact chemotherapeutic response oncologic outcomes . female patients tend better cancer-related response nac compared male patients.neoadjuvant chemotherapy used patients eligible cisplatin-combination chemotherapy; combinations (or monotherapies) inferior metastatic bc fully tested neoadjuvant setting [263-270]. 7.1.2.1. summary available data several phase iii rcts addressed potential survival benefit nac administration [263-267,271-274]. main differences trial designs type chemotherapy (i.e., single-agent cisplatin combination chemotherapy) number cycles provided. patients fit cisplatin. since studies differed considerably patient numbers, patient characteristics (e.g., clinical t-stages included) type definitive treatment offered (cystectomy and/or rt), pooling results possible. three meta-analyses undertaken establish nac prolongs survival [268-270]. meta-analysis including updated patient data 11 randomised trials (n = 3,005), significant survival benefit shown favour nac . recent meta-analysis included four additional rcts, used updated results nordic i, nordic ii, ba06 30894 trials including data 427 new patients updated information 1,596 patients. results analysis confirmed previously published data showed 8% absolute improvement survival five years number needed-to-treat 12.5 . cisplatin-combination chemotherapy least one additional chemotherapeutic agent resulted meaningful therapeutic benefit ; regimens tested methotrexate, vinblastine, adriamycin (epirubicin) plus cisplatin (mva(e)c), cisplatin, methotrexate plus vinblastine (cmv), cisplatin plus methotrexate (cm), cisplatin plus adriamycin cisplatin plus 5-fluorouracil (5-fu) . updated analysis large phase iii rct median follow-up eight years confirmed previous results provided additional findings: 16% reduction mortality risk;improvement 10-year survival 30% 36% neoadjuvant cmv;benefit regard distant metastases;the addition neoadjuvant cmv provided benefit locoregional control locoregional dfs, independent definitive treatment. modern chemotherapeutic regimens gc shown similar pt0/pt1 rates methotrexate, vinblastine, adriamycin plus cisplatin retrospective series pooled data analyses [276-279]. modified dd-mvac tested two small single-arm phase ii studies demonstrating high rates pathologic complete remission . moreover, large cross-sectional analysis showed higher rates down-staging pathological complete response dd-mvac . getug/afu v05 vesper rct peri-operative chemotherapy, 500 patients randomised either 6 cycles dd-mvac every 2 weeks vs. 4 cycles gc every 3 weeks prior surgery (neoadjuvant group) surgery (adjuvant group) primary endpoint progression-free survival (pfs) 3 years. 493 patients (437 neoadjuvant 56 adjuvant), similar pathologic response rate (ypt0n0) patients treated dd-mvac 42% gc 36% (p = 0.2) seen. < ypt2n0 rate 63% 50% dd-mvac gc patients, respectively. organ-confined response (< ypt3n0) observed frequently dd-mvac arm (77% vs. 63%, p = 0.001). patients trial, 3-year pfs improved dd-mvac arm, study meet primary endpoint (3-year rate: 64% vs. 56%, hr: 0.77 [95% ci: 0.57–1.02], p = 0.066); nevertheless, dd-mvac arm associated significantly longer time progression (3-year rate: 69% vs. 58%, hr: 0.68 [95% ci: 0.50–0.93], p = 0.014). neoadjuvant group, pfs 3 years significantly higher dd-mvac arm (66% vs. 56%, hr: 0.70 [95% ci: 0.51–0.96], p = 0.025). dose- dense mvac associated severe asthenia gi side effects gc . single-center retrospective analysis patients mibc, neoadjuvant accelerated mvac safe efficacious irrespective age, provided patients fit deemed suitable candidates cisplatin . another dose- dense regimen using gc reported two small phase ii trials . pathological response rates (< pt2) range 45%–57% achieved, one trial closed prematurely due high rates severe vascular events . approach therefore recommended outside clinical trials. alternative standard dose cisplatin-based nac 70 mg/m2 day 1, split-dose modifications regimens often used 35 mg/m2 days 1+8 days 1+2. retrospective analysis standard schedule compared split-dose schedule terms complete partial pathological response. lower number complete partial response rates seen split-dose group, results statistically significant . efforts aimed improving efficacy nac mibc ongoing. double- blind, randomised, placebo-controlled, phase ii neoblade trial neoadjuvant gemcitabine cisplatin chemotherapy nintedanib, small molecule inhibitor targets tyrosine kinases pdgfr, fgfr-1, vegfr-2, placebo, locally-advanced mibc, addition nintedanib chemotherapy safe improve rate pathological complete response . seem differences outcomes patients treated nac primary secondary mibc retrospective data suggesting patients primary mibc better pathologic response rates nac comparison patients secondary mibc . however, absence prospective data, patients secondary mibc treated similarly presenting primary mibc . unclear, patients non-uc histology also benefit nac. retrospective analysis demonstrated patients neuroendocrine tumours improved os lower rates non-organ-confined disease receiving neoadjuvant cisplatinum/etoposide chemotherapy. case micropapillary differentiation, sarcomatoid differentiation adenocarcinoma, lower rates non-organ confined disease found, statistically significant impact os. patients scc benefit nac . 2019 systematic review showed benefit nac patients micropapillary-, plasmacytoid-, sarcomatoid-, mixed variants especially patients neuroendocrine tumours . u.s. national cancer database study evaluating potential associations receipt nac, pathological downstaging os patients histological subtype mibc demonstrated nac associated pathological downstaging mibc histological subtypes (uc; sarcomatoid uc; micropapillary uc; scc; neuroendocrine carcinoma; adenocarcinoma), improved os patients uc, sarcomatoid variant uc neuroendocrine carcinoma . 7.1.3. role imaging predictive biomarkers (see also section 5.2) data small imaging studies aiming identify responders patients treated nac suggest response two cycles treatment predictive outcome. although mpmri advantage better resolution bladder wall tissue planes compared ct, ready yet standard patient care. however, bladder mpmri may useful inform tumour stage turb response nac . far pet/ct, mri dce-mri cannot accurately assess treatment response [292-295]. identify progression nac, imaging used many centres notwithstanding lack supporting evidence. responders nac, especially complete response (pt0 n0), treatment major positive impact os . therefore, reliable predictive markers identify patients likely benefit chemotherapy needed. study investigated molecular subtypes impact pathological response survival patients receiving pre-operative cisplatin-based chemotherapy . patients genomically unstable (gu) urothelial-like (uro) tumours higher proportions complete pathological response (16/31 [52%] 17/54 [31%] vs. 5/24 (21%) basal/squamous (ba/ sq) subtype) following nac rc. molecular subtype independently associated improved survival patients gu tumours (hr: 0.29, 95% ci: 0.11–0.79) uroc tumours (hr: 0.37, 95% ci: 0.14–0.94) compared ba/sq tumours, adjusting clinical stage. molecular tumour profiling might guide use nac future but, yet, applicable routine practice [299-301] (see chapter 6 - markers). 7.1.4. role neoadjuvant immunotherapy chemo-immunotherapy inhibition pd-1/pd-l1 checkpoint demonstrated significant benefit patients unresectable metastatic bc second-line setting platinum-ineligible pd-l1+ patients first-line treatment using different agents. checkpoint inhibitors increasingly tested also neoadjuvant setting; either monotherapy combination chemotherapy ctla-4 checkpoint inhibition. data two phase ii trials presented encouraging results . results pure-01, phase ii trial using pd-1 inhibitor pembrolizumab reported complete pathological remission (pt0) 42% pathological response (< pt2) 54% patients, whereas single-arm phase ii trial atezolizumab pathologic complete response rate 31% reported. update abacus trial using single-agent atezolizumab, two-year dfs os 68% (95% ci: 58–76) 77% (95% ci: 68–85), respectively two-year dfs patients achieving pathological complete response 85% (95% ci: 65–94) . update pure-01, median follow-up 39 months, 36-month efs os 74% (95% ci: 68-82) 84% (95% ci: 78-90), respectively rfs patients achieving complete pathologic response 96% (95% ci: 89-100) . combination anti-ctla4 anti-pd1 therapy also investigated neoadjuvant setting. nabucco study using pre-operative ipilimumab nivolumab, pathologic complete response 46% 58% remaining invasive disease (pt0n0/ptisn0/ptan0) . second study using pre-operative tremelimumab durvalumab cisplatin-ineligible patients, pathological complete response 37.5% downstaging pt1 less seen 58% patients completed surgery . three studies published date investigating use neoadjuvant chemo-immunotherapy patients mibc. phase ii study gemcitabine plus split-dose cisplatin pembrolizumab patients mibc, 22 39 patients (56% [95% ci: 40–72]) achieved < pt2n0 14 39 (36% [95% ci: 21–53]) achieved pt0n0 . second phase ii study evaluating neoadjuvant atezolizumab gemcitabine cisplatin; 27 39 patients (69%) < pt2n0 16 (41%) pt0n0. patient < pt2n0 relapsed four (11%) ≥ pt2n0 relapsed median follow-up 16.5 months (range: 7.0–33.7 months) . third phase ii study evaluating nac gc plus durvalumab including adjuvant durvalumab primary endpoint efs demonstrated efs 3 years 73% (95% ci, 59 83). complete pathologic response achieved 17 52 patients (33%), 31 (60%) pathologic response <ypt2 ypn0. overall survival (os) 81% (95% ci, 67 89) 3 years. promising pathologic response rates, several larger studies currently investigating potential role neoadjuvant chemo-immunotherapy patients mibc . present, results immunotherapy alone, combination chemotherapy, promising yet approved routine practice. 7.1.5. summary evidence guidelines neoadjuvant therapy summary evidenceleneoadjuvant cisplatin-containing combination chemotherapy improves os (8% five years).1aneoadjuvant treatment may major impact os patients achieve ypt0 ≤ ypt2.2acurrently immunotherapy checkpoint inhibitors monotherapy, different combinations without chemotherapy, tested phase ii iii trials. initial results promising.-there still reliable tools available select patients higher probability benefitting nac. future, genetic markers personalised medicine setting might facilitate selection patients nac differentiate responders non-responders.- recommendationsstrength ratingif eligible cisplatin-based chemotherapy, offer neoadjuvant cisplatin-based combination chemotherapy patients muscle-invasive bladder cancer (t2-t4a, cn0 m0).strongdo offer nac patients ineligible cisplatin-based combination chemotherapy.strongonly offer neoadjuvant immunotherapy patients within clinical trial setting.strong